Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial

BACKGROUND: Following the global eradication of wild poliovirus, countries using live attenuated oral poliovirus vaccines will transition to exclusive use of inactivated poliovirus vaccine (IPV) or fractional doses of IPV (f-IPV; a f-IPV dose is one-fifth of a normal IPV dose), but IPV supply and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandyopadhyay, Ananda S, Gast, Chris, Rivera, Luis, Sáez-Llorens, Xavier, Oberste, M Steven, Weldon, William C, Modlin, John, Clemens, Ralf, Costa Clemens, Sue Ann, Jimeno, Jose, Rüttimann, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992032/
https://www.ncbi.nlm.nih.gov/pubmed/33284114
http://dx.doi.org/10.1016/S1473-3099(20)30555-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992032/
https://www.ncbi.nlm.nih.gov/pubmed/33284114
http://dx.doi.org/10.1016/S1473-3099(20)30555-7

Ejemplares similares